Transport of CRH from mouse brain directly affects peripheral production of beta -endorphin by the spleen

J. Martin Martins, William A. Banks, and Abba J. Kastin

Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, Louisiana 70146

    ABSTRACT
Top
Abstract
Introduction
Methods
Results
Discussion
References

The blood-brain barrier (BBB) regulates the passage of substances between the brain and the periphery. It has not been shown that the secretion from the brain of a small amount of a substance can directly affect the periphery by transport across the BBB. We found that central injection of radioactively labeled corticotropin-releasing hormone (CRH) resulted in the accumulation of intact CRH in the spleen. CRH also increased splenic beta -endorphin, an effect not blocked by pretreatment with dexamethasone. Inhibition of the secretion of CRH from the brain by colchicine resulted in decreased accumulation of CRH in the spleen and also decreased splenic beta -endorphin. Similar findings occurred in the pituitary gland. The results show that the passage of labeled CRH from the brain can directly affect a peripheral organ, thus emphasizing the regulatory function of the BBB.

corticotropin-releasing hormone; blood-brain barrier; neuroimmunology; peptides

    INTRODUCTION
Top
Abstract
Introduction
Methods
Results
Discussion
References

BRAIN corticotropin-releasing hormone (CRH) mediates the integrated stress response and initiates adequate behavioral, endocrinologic, vegetative, autonomic, and immunological adaptation to physical and psychological challenges (7, 12). CRH plays a fundamental role in the homeostasis of the immune response. Antigenic stimuli, by means of lymphocyte production of cytokines, can induce CRH release, whereas CRH and other regulatory peptides and steroids of the hypothalamic-pituitary-adrenal axis (HPA) modulate the immune response (6, 11, 30). The effects of CRH are both central, through activation of the sympathetic nervous system and the HPA, and peripheral, because CRH acting directly on peripheral mononuclear blood cells can induce lymphocyte proliferation and the release of cytokines and proopiomelanocortin-derived (POMC) peptides (8, 28).

The anatomic and physiological characteristics of the blood-brain barrier (BBB) impose a separation between central and peripheral compartments in both the production and action of regulatory peptides. However, contrary to previous views, the BBB is not an absolute barrier, and selective passage through it has been shown to occur for small and large peptides (2, 3, 13). The physiological significance and pathological implications of such passage have not been fully studied.

In the rodent, we have shown previously that, whereas peripherally produced CRH is not able to reach the brain, a specific and active carrier-mediated transport system exists for the rapid transport of CRH from brain to blood (18, 19). This system was shown to be acutely modulated by adrenal steroids, cytokines, endogenous opiates, and opiate regulatory peptides, indicating it to be an integral part of the HPA and suggesting its relevance in the control of the stress response (18).

There is a widespread distribution of CRH within the central nervous system, including the cortex, limbic system, basal ganglia, brainstem gray matter, and cerebellum (29). The transport system from brain to blood for CRH could allow central sources of this peptide to contribute to peripheral blood levels.

Several direct peripheral effects of CRH have been described on peripheral mononuclear blood cells, testis, ovary, and placenta (8, 14, 20, 24, 31). Although it is generally assumed that these effects depend on peripheral, locally produced CRH by a paracrine or autocrine action of the peptide, the possibility remains that centrally produced CRH could cross the BBB and reach these peripheral sites in amounts sufficient to cause these effects.

To elucidate the physiological relevance of the unidirectional brain-to-blood transport system for CRH, we established three objectives for the present work: 1) to quantitatively evaluate the fraction of centrally administered CRH that reaches the blood, spleen, and pituitary; 2) to evaluate the effects of modulation of the brain-to-blood transport system for CRH on the amount reaching those target organs; and 3) to show peripheral effects of centrally administered CRH and its modulation by the BBB transport system.

    METHODS
Top
Abstract
Introduction
Methods
Results
Discussion
References

Adult male ICR mice (Charles River, Wilmington, MA), weighing 19-21 g, were used in all experiments, which were approved by the Institutional Animal Care and Use Committee. The mice were housed in group cages in rooms with controlled temperature, humidity, and light. Laboratory food and tap water were continuously available.

Human/rat CRH (hCRH) was obtained from Bachem (Torrance, CA). Iodine-125 (125I, sodium salt) was obtained from Amersham (Arlington Heights, IL). All other reagents were obtained from Sigma Chemical (St. Louis, MO).

Isotopic labeling of hCRH. Unaltered hCRH was labeled with 125I by the iodogen method described by Salacinsky et al. (25) and modified by Linton and Lowry (16), as previously used by us (18, 19), with the commercially available iodo-bead reagent (Pierce, Rockford, IL). The labeled peptide was separated from free 125I by chromatography on a C8 silica column (Variant Sample Preparation Products, Harbor City, CA), as previously described (18, 19), diluted in Ringer's lactate, stored at -70°C, and used within 2 wk.

Transport out of the brain and pituitary and spleen uptake. The previously described intracerebroventricular injection method was used (1). Briefly, mice were anesthetized by the intraperitoneal injection of 0.2 ml of 40% urethan. The anterior cervical region was dissected and the right carotid artery was isolated. The scalp was exposed, and a hole was made with a 26-gauge guarded needle, 1 mm lateral and 1 mm posterior to the bregma and 3.5 mm deep, to reach the lateral ventricle. At time 0, 1 µl of a solution of 125I-hCRH in Ringer's lactate [50,000 counts/min (cpm)] was injected into the lateral ventricle with a Hamilton syringe (Hamilton, Reno, NV). After 1.5, 5, 10, 20, 30, 40, 50, 60, and 90 min, the carotid artery was cut and 1 ml of arterial blood was collected. The animals were decapitated, and the brain (except for the pineal and pituitary), the pituitary, and the spleen were collected. The whole procedure was accomplished in <4 min for each animal. Radioactivity (cpm) in the brain, pituitary, and spleen and radioactivity (cpm/ml) in serum were counted for 1 min in a gamma counter. Results were expressed as the percentage of the administered dose and as counts per minute per whole organ. Ten animals were used at each time point.

The linear regression of brain radioactivity (log cpm) vs. experimental time (t) was computed: log cpm = alpha  + beta t, and the slope (beta ) was used as an index of the rate of the brain efflux (1). Common kinetic parameters were deduced by assuming a single-compartment model and first-order kinetics.

Chromatography of pituitary and spleen extracts. To characterize the radioactivity taken up by the pituitary and spleen after intracerebroventricular administration of 125I-hCRH, an extraction procedure followed by chromatography was used.

Mice were injected intracerebroventricularly with 1 µl of 125I-hCRH at time 0 as before. After 5 or 30 min, the animals were decapitated and the pituitaries and spleens were collected. To control for in vitro degradation, a group was used in which no intracerebroventricular injection of the labeled peptide was performed, but 1 µl of the 125I-hCRH was added directly to the spleen after organ collection. Ten animals were used for each experimental and control group.

For extraction, the pituitary and spleens were collected on dry ice, minced into small pieces, and boiled for 10 min; acetic acid was added to a final concentration of 0.1 M, and the mixture was homogenized and centrifuged for 20 min at 4°C. The supernatant was collected, and the pellet was again solubilized with 10 ml of a solution of 0.1 M acetic acid, followed by sonication and centrifugation. This second supernatant was added to the first, and the mixture was lyophilized. The extract was reconstituted in 250 µl of 0.1 M acetic acid and applied to the chromatography column.

The chromatographic procedure was the same as that used for the separation of free 125I and 125I-hCRH after isotopic labeling (18, 19). A silica column (Variant C8) was equilibrated by a wash with 20 ml of 1% trifluoroacetic acid (TFA), then with 20 ml of 80% methanol (MeOH), and finally with 20 ml of 1% bovine serum albumin (BSA) in Ringer's lactate. The extracted sample was eluted by gravity with 5 ml of 1% TFA, followed by 10 ml of 80% MeOH and then 10 ml of 1% TFA-80% MeOH. Fractions of 0.5 ml were collected, and the radioactivity was counted for 1 min in a gamma counter.

Pituitary and spleen uptake after inhibition of brain efflux. The same methodology as that in the initial experiments was used. However, at time 0, one group of 10 animals (controls) received 1 µl of a solution of 125I-hCRH as before, and the other group of 10 animals (experimental) also received 1 µl of a solution of 100 nmol colchicine in the contralateral ventricle. At 10, 20, and 30 min the brain, pituitary, and spleen were collected as before; the radioactivity was counted and expressed as a percentage of the administered dose. This dose of colchicine previously has been shown to inhibit by >50% the transport of CRH out of the brain (18). The area under the curve between 10 and 30 min was calculated by the trapezoidal rule (5).

Pituitary and spleen uptake after intravenous injection of 125I-hCRH. To evaluate the effect of intracerebroventricularly administered colchicine on the uptake of 125I-hCRH in the spleen and pituitary after intravenous injection of the labeled peptide, two groups of animals were used. One group (control) was given 1 µl of Ringer's lactate solution intracerebroventricularly 3 h before the intravenous injection, and the other group (experimental) was given 1 µl of a solution of 100 nmol colchicine 3 h before the injection.

Multiple time-regression analysis after intravenous injection of the labeled peptide was used as previously described (23). At time 0, 200 µl of 125I-hCRH (500,000 cpm) were injected into the left jugular vein. Blood was collected from the right carotid artery at 1, 5, 10, 20, 30, and 50 min.

Levels of radioactivity in serum (cpm/ml) and brain and spleen (cpm/g) were counted for 1 min. The parameter exposure time (ET) was derived from the equation
ET = (<IT>t</IT>) 10<SUP>−<IT>at</IT>/2</SUP>
where t is the experimental time, and a is the slope of the linear regression of blood radioactivity vs. experimental time. This correction is used to express blood concentrations of the labeled peptide as if a steady state existed between the different time intervals considered. Then the regression of the organ-to-blood ratio (R) vs. exposure time was computed
R = V<SUB>i</SUB> + <IT>K</IT><SUB>i</SUB> (ET)
whereby the y-intercept, Vi (ml/g), reflects the initial distribution of the labeled peptide, and the slope, Ki (ml · g-1 · min-1), is the rate of the transport of 125I-hCRH from the blood to the organ. Three animals were used at each time point.

Peripheral effects of centrally administered CRH. beta -endorphin levels in pituitary and spleen extracts were measured by radioimmunoassay (INCSTAR, Stillwater, MN) to evaluate the peripheral effects of hCRH. The assay has less than 1% cross-reactivity with other POMC-derived peptides except for beta -lipotropin (5.6%). The sensitivity is 0.2 pmol/organ.

Four groups of eight animals each were compared. For group A, the animals were injected intracerebroventricularly with 1 µl of Ringer's lactate solution; for group B, the animals were injected intracerebroventricularly with 1 µg hCRH; for group C, 0.2 ml of dexamethasone (0.2 mg/kg) was given intraperitoneally 4 h before the intracerebroventricular administration of 1 µg hCRH [this dose and schedule of dexamethasone administration have been shown to completely suppress peripheral blood levels of corticosterone (9, 33)]; for group D, 1 µl of 100 nmol colchicine was given intracerebroventricularly 3 h before the intracerebroventricular administration into the contralateral ventricle of 1 µg hCRH. One hour later the animals were decapitated, and the pituitaries and spleens were collected and extracted as recommended by the manufacturer.

Statistical analysis. Results are expressed as means ± SE. A statistical software package (BMDP Statistical Software, Los Angeles, CA) was used for analysis. Differences between groups were evaluated by one-way analysis of variance followed by post hoc Newman-Keuls multiple comparison tests when appropriate. Simple linear regression was used to relate the continuous variables and to compare regression lines.

    RESULTS
Top
Abstract
Introduction
Methods
Results
Discussion
References

125I-hCRH transport out of the brain. After intracerebroventricular administration of 125I-hCRH (50,000 cpm; <1 pmol), the percentage of the administered dose remaining in the brain decreased exponentially in relation to time: log(%dose) = 1.773 - 0.010 time (n = 9, r = 0.975, P < 0.0001; Fig. 1). For the transport out of brain for 125I-hCRH, with the assumptions of first-order kinetics and a single-compartment model, the estimated half-life of 125I-hCRH in brain was 30 (range of 25-38) min, the apparent initial volume of distribution at time 0 in brain was 0.618 (0.513-0.745) g, and the clearance rate was 0.014 (0.008-0.023) g/min.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Brain radioactivity (with 95% confidence limits) after icv administration of 125I-labeled human/rat corticotropin-releasing hormone (125I-hCRH). Line is based on equation log(% dose) = 1.773 - 0.010 (time). cpm, Counts/min.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Whole blood radioactivity after icv administration of 125I-hCRH. Line is based on the equation %dose = 27 + 0.486 (time) - 0.005 (time)2.

125I-hCRH: Blood levels. After intracerebroventricular administration of the labeled compound, the percentage of the administered dose in the total blood volume (estimated as 6.8 ml, with no significant differences in the radioactivity distributed between plasma and cellular fractions) showed a parabolic relation to time, defined by a second-degree equation: %dose = 27 + 0.486 time - 0.005 (time)2 (n = 9, r = 0.772, P < 0.01; Fig. 2).

Elimination kinetics from blood were represented by the log-linear regression: log (cpm/ml) = 3.531 - 0.002 time (n = 5, r = 0.951, P < 0.02), resulting in an estimated half-life in blood for 125I-hCRH of 151 (96-352) min. The log-linear regression was log (cpm/ml) = 3.241 - 0.032 time (n = 4, r = 0.986, P < 0.02), resulting in an absorption half-life of 9 (6-19) min.

With the assumption of a constant-rate infusion from brain resulting from the brain-to-blood transport just considered, then, at steady state, blood concentrations of the peptide will approach 0.318 that of the cerebrospinal fluid (CSF) concentration of the peptide: Css = R/Cl, where Css is the steady-state blood concentration of the peptide, R is the infusion rate, and Cl is the blood clearance of the peptide.

125I-hCRH: Pituitary levels. Figure 3 shows the relationship between pituitary levels of the labeled peptide vs. time after intracerebroventricular administration of 125I-hCRH. Elimination kinetics were expressed by the regression equation log cpm = 2.413 - 0.010 time (n = 6, r = 0.963, P < 0.002), resulting in a computed half-life of the labeled peptide in the pituitary of 30 (22-49) min.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Pituitary radioactivity after icv administration of 125I-hCRH. Best-fit line represented was drawn without consideration of the last (90-min) time point.

With the assumption of constant blood levels of the peptide at the steady state, pituitary levels will be ~22.5 times the blood levels, according to the relationship: Ass = R/Kel, where Ass is the amount in the organ at steady state, R is the infusion rate, and Kel is the elimination rate constant. The percentage of the administered dose, however, is lower.

125I-hCRH: Spleen levels. After intracerebroventricular injection of the labeled peptide, there was a cyclic pattern in the levels of 125I-hCRH in the spleen (Fig. 4). If only the first seven time points are considered, 1.5-50 min, the percentage of the administered dose in spleen followed a parabolic relationship to time: %dose = 0.074 + 0.027 time - 0.001 (time)2 (n = 7, r = 0.813, P < 0.05).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Splenic radioactivity after icv administration of 125I-hCRH. Best-fit line represented was drawn without consideration of the last two (60- and 90-min) time points.

Absorption kinetics followed a first-order kinetic model: log cpm = 3.132 - 0.035 time (n = 4, r = 0.998, P < 0.002), resulting in an estimated absorption half-life of 9 (7-10) min. With the assumption of constant blood levels of the peptide at steady state, the spleen level of the peptide was ~1.5 times that of the blood.

Identity of the material taken up by pituitary and spleen. Chromatography of the control sample extracts of spleen revealed that, when the labeled material was added after organ collection but before the extraction procedure, 65% of the material eluted at the position of intact 125I-hCRH, and 26% eluted at the position of free 125I. There were no peaks eluting at the position of labeled peptide fragments.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Chromatography of pituitary and splenic extracts obtained 5 min after icv administration of 125I-hCRH. In each case, 8 mice were used, and organs were pooled. First peak represents free 125I, and the larger peak represents 125I-hCRH.

When the pituitaries or spleens were collected 5 min after intracerebroventricular injection of 125I-hCRH, 23% (pituitary) and 43% (spleen) of the applied material eluted at the position of the intact peptide, 31 and 29% eluted at the position of free 125I, and there were two peaks with a total of 9 and 13% eluting at the position of labeled peptide fragments (Fig. 5).

When spleen collection occurred 30 min after intracerebroventricular injection of the labeled peptide, 75% of the material recovered eluted in the position of free 125I, only 8% eluted in the position of intact 125I-hCRH, and two small peaks corresponding to labeled peptide fragments amounted to 13%.

Pituitary and spleen uptake after inhibition of brain efflux. In relation to controls, animals treated with 100 nmol colchicine intracerebroventricularly 3 h before the administration of 125I-hCRH in the contralateral ventricle showed significantly (P < 0.05) greater retention of radioactivity in the brain at 10, 20, and 30 min. For the pituitary, the values for radioactivity after intracerebroventricular administration of 125I-hCRH between 10 and 30 min were significantly lower after intracerebroventricular colchicine (0.79 ± 0.12 vs. 0.45 ± 0.08%, P < 0.05). Similarly for the spleen, colchicine significantly lowered the uptake of peptide (0.55 ± 0.05 vs. 0.46 ± 0.05%, P < 0.05).

Organ uptake after intravenous injection of 125I-hCRH. There was no evidence for brain uptake of 125I-hCRH after intravenous injection of the labeled peptide. Multiple regression analysis did not show any significant difference in animals treated 3 h before with colchicine (100 nmol icv) compared with controls injected intracerebroventricularly with Ringer's lactate.

After intravenous injection of the labeled peptide, there was significant uptake of 125I-hCRH by the pituitary. In relation to controls, animals treated with colchicine (100 nmol icv) 3 h before showed a significantly (P < 0.05) greater uptake (higher Ki) and also a significantly (P < 0.05) greater initial volume of distribution (higher Vi) within the organ, as determined by multiple regression analysis. Splenic uptake of the labeled peptide after intravenous injection was significant vs. time but not significantly different between animals previously treated with colchicine intracerebroventricularly and controls, as shown by multiple regression analysis.

beta -Endorphin content in the pituitary and spleen. The content of beta -endorphin in the pituitary and spleen was significantly increased after administration of 1 µg hCRH intracerebroventricularly. Previous administration of intraperitoneal dexamethasone significantly reduced the content of beta -endorphin in the pituitary but not in the spleen. Previous intracerebroventricular injection of colchicine significantly reduced beta -endorphin in the pituitary and spleen to levels not significantly different from basal values (Fig. 6).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   beta -Endorphin content in pituitary and spleen. Group A, 1 µl Ringer's lactate icv; group B, 1 µg hCRH icv; group C, 1 µg hCRH icv + 0.2 mg/kg dexamethasone ip 4 h previously; group D: 1 µg hCRH icv + 100 nmol colchicine icv 3 h previously. a P < 0.05; b P < 0.10.

    DISCUSSION
Top
Abstract
Introduction
Methods
Results
Discussion
References

Although CRH from the hypothalamus can reach the periphery, this probably is not a major source of peripherally circulating CRH. CRH from other central sites such as the cortex and limbic system probably contributes more to peripheral levels. The release of this CRH appears to be controlled differently from that of the hypothalamus, as further shown by differences in diurnal rhythm and response to stress (22, 27, 32).

Centrally produced CRH also could reach the periphery by the slow reabsorption of CSF. However, this is a nonspecific process with a half-life of ~45 min. The fastest way for central CRH to reach the periphery is through rapid passage across the BBB by the previously described specific, active, carrier-mediated unidirectional transport system from brain to blood (18, 19).

Our first experiment showed that, after central administration of CRH, the portion reaching the peripheral circulation is relatively large. After intracerebroventricular injection of 125I-hCRH, the amount in brain decreased exponentially, with an apparent half-life of 30 min. This agrees well with previous work (18, 19), although the time is at the end of the range. This can be readily explained by two experimental factors. First, in this study, experimental times were longer (up to 90 min), so that the slow reabsorption of CRH along with CSF could be relevant. Consideration of only the first five time points (1.5-30 min) shows an apparent half-life of 23 min, closer to the middle of the previously reported range. Second, we used a larger dose of 125I-hCRH in this report; because the transport system has limited capacity, this might have exerted a small saturating effect.

The amount of the labeled peptide in the estimated whole blood volume after central administration followed a clear parabolic relationship vs. experimental time, similar to what would result from other routes of administration. Basic kinetic parameters deduced from these blood levels suggest a first-order absorption process with an estimated half-life of 9 min, comparing well with the elimination half-life from brain. This indicates a rapid process that is more compatible with the brain-to-blood transport system described than with the reabsorption of CSF.

The computed elimination half-life in blood also is longer than previously reported (19, 26). This may depend on the long time period used in its computation (30-90 min) and on the different route of administration (icv vs. iv). Under physiological conditions at steady state, given the relationship between absorption and elimination constants for blood, it can be estimated that the concentration of peptide in blood will approach one-third the concentration in CSF. Human studies have reported plasma levels of CRH in the range of 2-28 pg/ml (4, 17, 27), whereas concentrations in human CSF are at least 3-4 times higher [9-17 pmol/l approx  40-80 pg/ml (10, 15)]. Thus central CRH and the transport system previously described can account for all the reported blood levels of the peptide.

After central administration of 125I-hCRH, the labeled peptide quickly reached the pituitary and spleen, where peak values were found at 10 and 30 min, respectively. Basic kinetic analysis indicated low-order absorption kinetics (half-life <1.5 min) for the pituitary and first-order absorption kinetics for the spleen (half-life = 9 min). It is estimated that, at steady state, the content of CRH in spleen is ~1.5 times the levels in blood, whereas maximal content in pituitary is ~23 times blood levels.

Results from the second set of experiments indicate that the material taken up by the pituitary and spleen after intracerebroventricular administration of the labeled peptide represents mostly intact peptide. Five minutes after intracerebroventricular administration of 125I-hCRH, more than one-half of the radioactivity in the pituitary and more than two-thirds of the radioactivity in the spleen eluted at the position of the intact peptide.

The much shorter absorption half-lives of CRH for both the pituitary and spleen in relation to the longer half-lives of elimination from blood reported in other studies (19, 26) also are consistent with the amount taken up corresponding to most of the intact peptide. Supporting this is the smaller percentage found in the pituitary, expected from its faster uptake than in the spleen.

Previous work (18) suggested that the brain-to-blood transport system for CRH probably corresponds to a transcytotic process, because it can be inhibited by intracerebroventricular administration of colchicine, the prototypic drug known to interfere with the microtubular system. In the third set of experiments, intracerebroventricular administration of colchicine in a dose known to inhibit the transport of CRH out of the brain significantly increased the amount of the intracerebroventricularly administered 125I-hCRH retained in the brain at 10, 20, and 30 min.

This set of experiments showed that the effect of colchicine on the uptake of CRH by the pituitary and spleen was not exerted directly on these peripheral organs. As was also found previously (18, 19), there was no evidence of brain uptake of 125I-hCRH after intravenous injection, and this was not influenced by the previous administration of intracerebroventricular colchicine. Thus the results indicate that the decreased uptake of labeled CRH by the pituitary and spleen after pretreatment with colchicine is explained by the known ability of colchicine to decrease the transport of CRH out of the brain.

The last set of experiments demonstrated that intracerebroventricular administration of CRH at the low dose of 1 µg (0.2 nmol) significantly increased the content of beta -endorphin in the spleen and pituitary. The effect was rapid, being evident 1 h after intracerebroventricular injection of the peptide. This supports the reports that subcutaneous CRH and intracerebroventricular interleukin-1alpha significantly increase the concentration of beta -endorphin in the spleen (21, 24). The effect of the intracerebroventricular interleukin-1alpha was probably mediated by CRH, because it could be blocked by previous administration of a specific CRH antagonist.

The dose of dexamethasone we used reduced the pituitary content of beta -endorphin, as might be expected from its known (9) ability to completely suppress levels of corticosterone in the serum. Yet the dexamethasone did not significantly reduce the splenic content of beta -endorphin, suggesting different regulatory systems in these organs.

Central administration of colchicine, in doses that inhibited the transport of CRH out of the brain, reduced the content of beta -endorphin in both the spleen and the pituitary to levels indistinguishable from basal values. beta -endorphin in the spleen probably is produced there, because hypophysectomy does not affect its content (24). Because colchicine did not affect the uptake of intravenous CRH, the evidence indicates that it was the decreased release of CRH from the brain that resulted in the reduction in splenic beta -endorphin.

In conclusion, kinetic analysis of a single central intracerebroventricular injection of a small amount of 125I-hCRH shows that the brain-to-blood transport system for CRH can result in meaningful amounts of this peptide in blood, pituitary, and spleen. Modulation of the release of central CRH can alter its effects on peripheral organs. This indicates that endogenous central CRH can easily and quickly cross the BBB to reach the periphery in amounts sufficient to produce physiological effects.

    ACKNOWLEDGEMENTS

We thank Melita B. Fasold for help in preparation of the manuscript.

    FOOTNOTES

J. Martin Martins is a visiting endocrinologist from Curry Cabral Hospital, Lisbon, Portugal.

This study was supported by the Veterans Administration and the Office of Naval Research.

Address for reprint requests: W. A. Banks, VA Medical Center, 1601 Perdido St., New Orleans, LA 70146.

Received 20 March 1997; accepted in final form 8 August 1997.

    REFERENCES
Top
Abstract
Introduction
Methods
Results
Discussion
References

1.   Banks, W. A., and A. J. Kastin. Quantifying carrier-mediated transport of peptides from the brain to the blood. In: Methods in Enzymology, edited by P. M. Conn. San Diego, CA: Academic, 1989, vol. 168, p. 652-660.

2.   Banks, W. A., and A. J. Kastin. Bidirectional passage of peptides across the blood-brain barrier. In: Progress in Brain Research, edited by A. Ermisch, R. Landgraf, and H.-J. Rühle. Amsterdam: Elsevier Science, 1992, vol. 91, p. 139-148.

3.   Banks, W. A., and A. J. Kastin. Physiological consequences of the passage of peptides across the blood-brain barrier. Rev. Neurosci. 4: 365-372, 1993[Medline].

4.   Behan, D. P., O. Khongsaly, X. Liu, N. Ling, R. Goland, B. Nasman, T. Olsson, and E. B. De Souza. Measurement of corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in human plasma by two-site enzyme-linked immunoabsorbant assay. J. Clin. Endocrinol. Metab. 81: 2579-2586, 1996[Abstract].

5.   Bruhn, T. O., P. M. Plotsky, and W. W. Vale. Effect of paraventricular lesions on corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: studies on the adrenocorticotropin response to ether stress and exogenous CRF. Endocrinology 114: 57-62, 1984[Abstract].

6.   Chrousos, G. P. Regulation and dysregulation of the hypothalamic-pituitary-adrenal axis. Endocrinol. Metab. Clin. North Am. 21: 833-858, 1992[Medline].

7.   Chrousos, G. P., and P. W. Gold. The concepts of stress and stress system disorders. JAMA 267: 1244-1252, 1992[Abstract].

8.   Clarke, B. L., B. M. Gebhardt, and J. E. Blalock. Mitogen-stimulated lymphocytes release biologically active corticotropin. Endocrinology 132: 983-988, 1993[Abstract].

9.   Fleshner, M., L. R. Watkins, L. L. Lockwood, R. E. Grahn, G. Gerhardt, M. J. Meany, M. L. Laudenslager, and S. F. Maier. Blockade of the hypothalamic-pituitary-adrenal response to stress by intraventricular injection of dexamethasone: a method for studying the stress-induced peripheral effects of glucocorticoids. Psychoneuroendocrinology 18: 251-263, 1993[Medline].

10.   Geracioti, T. D., D. N. Orth, N. N. Ekhator, B. Blumenkopf, and P. Loosen. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J. Clin. Endocrinol. Metab. 74: 1325-1330, 1992[Abstract].

11.   Imura, H., J. Fukata, and T. Mori. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin. Endocrinol. 35: 107-115, 1991[Medline].

12.   Johnson, E. O., T. C. Kamilaris, G. P. Chrousos, and P. W. Gold. Mechanisms of stress: a dynamic overview of hormonal and behavioral homeostasis. Neurosci. Biobehav. Rev. 16: 115-130, 1992[Medline].

13.   Kastin, A. J., J. E. Zadina, R. D. Olson, and W. A. Banks. The history of neuropeptide research: version 5.a. Ann. NY Acad. Sci. 780: 1-18, 1996[Medline].

14.   Kavelaars, A., F. Berkenbosch, G. Croiset, R. E. Ballieux, and C. J. Heijnen. Induction of beta -endorphin secretion by lymphocytes after subcutaneous administration of corticotropin-releasing factor. Endocrinology 126: 759-764, 1990[Abstract].

15.   Kling, M. A., M. D. DeBellis, D. K. O'Rourke, S. Listwak, T. D. Geracioti, I. E. McCutcheon, K. T. Kalogeras, E. H. Oldfield, and P. W. Gold. Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers. J. Clin. Endocrinol. Metab. 79: 233-239, 1994[Abstract].

16.   Linton, E. A., and P. J. Lowry. Radioimmunoassay and chromatographic characterisation of CRF-41-like immunoreactivity in hypothalami from several species. Neuropeptides 3: 45-52, 1982[Medline].

17.   Linton, E. A., C. McLean, A. C. N. Kruseman, F. J. H. Tilders, E. A. Van der Veen, and P. J. Lowry. Direct measurement of human plasma corticotropin-releasing hormone by "two-site" immunoradiometric assay. J. Clin. Endocrinol. Metab. 64: 1047-1053, 1987[Abstract].

18.   Martin Martins, J., W. A. Banks, and A. J. Kastin. Acute modulation of active carrier-mediated brain-to-blood transport of corticotropin-releasing hormone. Am. J. Physiol. 272 (Endocrinol. Metab. 35): E312-E319, 1997[Abstract/Free Full Text].

19.   Martin Martins, J., A. J. Kastin, and W. A. Banks. Unidirectional specific and modulated brain to blood transport of corticotropin-releasing hormone. Neuroendocrinology 63: 338-348, 1996[Medline].

20.   Mastorakos, G., C. D. Scopa, A. Vryonidou, T. C. Friedman, D. Kattis, C. Phenekos, M. J. Merino, and G. P. Chrousos. Presence of immunoreactive corticotropin-releasing hormone in normal and polycystic human ovaries. J. Clin. Endocrinol. Metab. 79: 1191-1197, 1994[Abstract].

21.   McGillis, J. P., A. Park, P. Rubin-Fletter, C. Turck, M. F. Dallman, and D. G. Payan. Stimulation of rat B-lymphocyte proliferation by corticotropin-releasing factor. J. Neurosci. Res. 23: 346-352, 1989[Medline].

22.   Menzaghi, F., S. C. Heinrichs, E. M. Pich, F. Weiss, and G. F. Koob. The role of limbic and hypothalamic corticotropin-releasing factor in behavioral responses to stress. Ann. NY Acad. Sci. 697: 142-154, 1993[Abstract].

23.   Patlak, C. S., R. G. Blasberg, and J. D. Fenstermacher. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3: 1-7, 1983[Medline].

24.   Sacerdote, P., M. Bianchi, B. Manfredi, and A. E. Panerai. Intracerebroventricular interleukin-1alpha increases immunocyte beta -endorphin concentrations in the rat: involvement of corticotropin-releasing hormone, catecholamines, and serotonin. Endocrinology 135: 1346-1352, 1994[Abstract].

25.   Salacinski, P. R. P., C. McLean, J. E. C. Sykes, V. V. Clement-Jones, and P. J. Lowry. Iodination of proteins, glycoproteins and peptides using a solid phase oxidising agent, 1,3,4,6-tetrachloro-3alpha ,6alpha diphenyl glycoluril (Iodogen). Anal. Biochem. 117: 136-146, 1981[Medline].

26.   Saphier, P. W., M. Faria, A. Grossman, D. H. Coy, G. M. Besser, B. Hodson, M. Parkes, E. A. Linton, and P. J. Lowry. A comparison of the clearance of ovine and human corticotropin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. J. Endocrinol. 133: 487-495, 1992[Abstract].

27.   Sasaki, A., S. Sato, O. Murakami, M. Go, M. Inoue, Y. Shimizu, K. Hanew, N. Andoh, I. Sato, N. Sasano, and K. Yoshinaga. Immunoreactive corticotropin-releasing hormone present in human plasma may be derived from both hypothalamic and extrahypothalamic sources. J. Clin. Endocrinol. Metab. 65: 176-182, 1987[Abstract].

28.   Smith, E. M., A. C. Morrill, W. J. Meyer III, and J. E. Blalock. Corticotropin releasing factor induction of leukocyte-derived immunoreactive ACTH and endorphins. Nature 321: 881-882, 1986[Medline].

29.   Swanson, L., P. E. Sawchenko, J. Rivier, and W. W. Vale. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36: 165-186, 1983[Medline].

30.   Tilders, F. J. H., R. H. DeRijk, A. Van Dam, V. A. M. Vincent, K. Schotanus, and J. H. A. Persoons. Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology 19: 209-232, 1994[Medline].

31.   Ulisse, S., A. Fabbri, and M. L. Dufau. Corticotropin-releasing factor receptors and actions in rat Leydig cells. J. Biol. Chem. 264: 2156-2163, 1989[Abstract/Free Full Text].

32.   Veldhius, H. D., and D. De Wied. Differential behavioral actions of corticotropin-releasing factor (CRF). Pharmacol. Biochem. Behav. 21: 707-713, 1984[Medline].

33.   Zhukov, D. A. The dexamethasone suppression test in genetically different rats exposed to inescapable and escapable electric shocks. Psychoneuroendocrinology 18: 467-474, 1993[Medline].


AJP Endocrinol Metab 273(6):E1083-E1089
0193-1849/97 $5.00 Copyright © 1997 the American Physiological Society